Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial

Combining pharmacological treatment with lifestyle interventions has long been considered the ideal approach to obesity management. The STEP 3 trial by Wadden, Bailey, Billings, and colleagues, published in JAMA, tested whether adding semaglutide to intensive behavioral therapy could enhance weight loss outcomes beyond either approach alone.

The randomized clinical trial enrolled adults with overweight or obesity and combined subcutaneous semaglutide with an intensive behavioral therapy program that included dietary counseling, physical activity guidance, and behavioral modification techniques. This integrated design tested the synergy between pharmacological and lifestyle interventions.

The STEP 3 results showed that semaglutide combined with intensive behavioral therapy produces even greater weight loss than either approach alone. This synergistic effect demonstrated the power of integrating pharmaceutical innovation with evidence-based lifestyle modification.

For patients and clinicians, this study reinforces the value of a comprehensive treatment approach to obesity. The combination of semaglutide's powerful pharmacological effects with structured behavioral support creates a more effective treatment paradigm that addresses obesity from multiple angles, maximizing the potential for meaningful and lasting weight management.